Gerald Gartlehner

Gerald Gartlehner's AcademicInfluence.com Rankings

Gerald Gartlehner

Medical

#917

World Rank

#1180

Historical Rank

Epidemiology

#228

World Rank

#243

Historical Rank

medical Degrees

Gerald Gartlehner

Political Science

#2605

World Rank

#3065

Historical Rank

Public Policy

#200

World Rank

#207

Historical Rank

political-science Degrees

Download Badge

Medical
Political Science

Gerald Gartlehner's Degrees

Doctorate Medicine Medical University of Vienna
PhD Medical Sciences Medical University of Vienna

Why Is Gerald Gartlehner Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Gerald Gartlehner is an Austrian physician, health scientist and clinical epidemiologist. Considered a pioneer in the field of evidence-based medicine in Austria, Gartlehner has dedicated much of his career to establishing and promoting the use of evidence syntheses to make sound clinical and health policy decisions. Gartlehner was ranked in the top 1% of highly cited researchers in 2020, 2021, 2022 and 2023.

(See a Problem?)

Gerald Gartlehner's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Perinatal Depression: A Systematic Review of Prevalence and Incidence (2005) (2756)
Perinatal depression: prevalence, screening accuracy, and screening outcomes. (2005) (1446)
Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. (2020) (821)
[GRADE guidelines: 7. Rating the quality of evidence - inconsistency]. (2012) (680)
[GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables]. (2012) (665)
[GRADE guidelines: 8. Rating the quality of evidence - indirectness]. (2012) (602)
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis (2008) (482)
Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. (2011) (466)
Outcomes of routine episiotomy: a systematic review. (2005) (433)
[GRADE guidelines 15: going from evidence to recommendation - determinants of a recommendation's direction and strength]. (2014) (393)
GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. (2018) (358)
The GRADE Working Group clarifies the construct of certainty of evidence. (2017) (335)
Comparative Benefits and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder (2011) (324)
Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis (2008) (324)
Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. (2014) (271)
The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. (2006) (264)
Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews (2020) (259)
Grading the Strength of a Body of Evidence When Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update (2013) (254)
The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. (2013) (250)
Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder (2005) (237)
Socioeconomic inequalities in non-communicable diseases and their risk factors: an overview of systematic reviews (2015) (234)
Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians (2008) (229)
A simple and valid tool distinguished efficacy from effectiveness studies. (2006) (216)
Criteria for Distinguishing Effectiveness From Efficacy Trials in Systematic Reviews (2006) (203)
[Communicating Risk in Public Health Emergencies: A WHO Guideline for Emergency Risk Communication (Erc) Policy and Practice]. (2019) (191)
Cesarean delivery on maternal request. (2006) (190)
Impact of timing of surgery in elderly hip fracture patients: a systematic review and meta-analysis (2018) (188)
Grading the strength of a body of evidence when assessing health care interventions: an EPC update. (2015) (183)
[GRADE guidelines: 9. Rating up the quality of evidence]. (2013) (160)
Prevalence of mental disorders in young refugees and asylum seekers in European Countries: a systematic review (2018) (150)
[GRADE guidelines: 5. Rating the quality of evidence: publication bias]. (2012) (149)
[GRADE guidelines: 2. Framing the question and deciding on important outcomes]. (2012) (147)
Defining treatment‐resistant depression (2020) (145)
Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis (2015) (136)
Comparative Risk for Harms of Second Generation Antidepressants (2008) (134)
Efficacy and Safety of Inhaled Corticosteroids in Patients With COPD: A Systematic Review and Meta-Analysis of Health Outcomes (2006) (129)
The skills and experience of GRADE methodologists can be assessed with a simple tool. (2016) (128)
Comparative Effectiveness Review Methods: Clinical Heterogeneity (2010) (127)
Assessing applicability when comparing medical interventions: AHRQ and the Effective Health Care Program. (2011) (127)
Interventions to prevent post-traumatic stress disorder: a systematic review. (2013) (117)
P-1102 - Comparative Effectiveness of Second Generation Antidepressants in the Pharmacologic Treatment of Adult Depression (2011) (114)
Management of eating disorders. (2006) (114)
[GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence]. (2013) (108)
Excluding non-English publications from evidence-syntheses did not change conclusions: a meta-epidemiological study. (2019) (107)
Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. (2008) (107)
Serious adverse events with infliximab: analysis of spontaneously reported adverse events. (2007) (106)
Cesarean Delivery on Maternal Request: Maternal and Neonatal Outcomes (2006) (104)
Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for the US Preventive Services Task Force (2017) (104)
[GRADE: Evidence to Decision (EtD) frameworks - a systematic and transparent approach to making well informed healthcare choices. 1: Introduction]. (2018) (103)
Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder: Results from a Systematic Review with Network Meta-Analysis (2013) (96)
Effects of lifestyle changes on adults with prediabetes: A systematic review and meta-analysis. (2018) (96)
Vitamin D deficiency as a risk factor for dementia: a systematic review and meta-analysis (2017) (95)
Comparative Benefits and Harms of Antidepressant, Psychological, Complementary, and Exercise Treatments for Major Depression: An Evidence Report for a Clinical Practice Guideline From the American College of Physicians (2016) (90)
Functional Outcomes of Drug Treatment in Alzheimer’s Disease (2007) (89)
Light therapy for preventing seasonal affective disorder. (2015) (88)
Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews (2017) (88)
Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence (2007) (84)
[WHO Guideline for the Pharmacological Treatment of Hypertension in Adults]. (2023) (82)
[WHO Guidelines on Tuberculosis Infection Prevention and Control]. (2020) (80)
Identifying outcomes for depression that matter to patients, informal caregivers, and health-care professionals: qualitative content analysis of a large international online survey. (2020) (72)
How effective are common medications: a perspective based on meta-analyses of major drugs (2015) (72)
Quarantine alone or in combination with other public health measures to control COVID‐19: a rapid review (2020) (72)
Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents. (2011) (70)
COMPARATIVE EFFECTIVENESS OF SECOND‐GENERATION ANTIDEPRESSANTS FOR ACCOMPANYING ANXIETY, INSOMNIA, AND PAIN IN DEPRESSED PATIENTS: A SYSTEMATIC REVIEW (2012) (66)
Single-reviewer abstract screening missed 13 percent of relevant studies: a crowd-based, randomized controlled trial. (2020) (66)
Assessing the Applicability of Studies When Comparing Medical Interventions (2010) (66)
The use of episiotomy in obstetrical care: a systematic review. (2005) (64)
Household interventions for preventing domestic lead exposure in children. (2016) (63)
[Prevention of Mother-To-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy]. (2022) (63)
Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. (2013) (62)
Direct versus indirect comparisons: A summary of the evidence (2008) (62)
Semi-automating the manual literature search for systematic reviews increases efficiency. (2010) (62)
[GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes]. (2013) (62)
[GRADE guidelines: 3. Rating the quality of evidence (confidence in the estimates of effect)]. (2012) (58)
Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults (2011) (57)
[WHO Guideline: Counselling of women to Improve Breastfeeding Practices]. (2019) (56)
Definition of Treatment-Resistant Depression in the Medicare Population (2018) (55)
[GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health]. (2018) (55)
Universal screening for SARS-CoV-2 infection: a rapid review. (2020) (54)
Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis (2005) (51)
The performance of anthropometric tools to determine obesity: a systematic review and meta-analysis (2020) (50)
Cochrane Rapid Reviews Methods Group to play a leading role in guiding the production of informed high-quality, timely research evidence syntheses (2016) (49)
Benefits and harms of screening for and treatment of asymptomatic bacteriuria in pregnancy: a systematic review (2016) (49)
Abbreviated literature searches were viable alternatives to comprehensive searches: a meta-epidemiological study. (2018) (46)
[GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles - continuous outcomes]. (2014) (45)
Controlling for Drug Dose in Systematic Review and Meta-Analysis: A Case Study of the Effect of Antidepressant Dose (2009) (44)
Bach Flower Remedies for psychological problems and pain: a systematic review (2009) (44)
Clinical outcome after microfracture of the knee: a meta-analysis of before/after-data of controlled studies (2012) (43)
The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. (2020) (43)
Sex-specific differences in diabetes prevention: a systematic review and meta-analysis (2015) (43)
Assessing the need to update prevention guidelines: a comparison of two methods. (2004) (42)
Restricting evidence syntheses of interventions to English-language publications is a viable methodological shortcut for most medical topics: a systematic review: Excluding English-language publications a valid shortcut. (2021) (41)
Methods for the Drug Effectiveness Review Project (2012) (40)
Health effects of cow’s milk consumption in infants up to 3 years of age: a systematic review and meta-analysis (2015) (40)
Increased risks for random errors are common in outcomes graded as high certainty of evidence. (2019) (40)
Second-generation antidepressants for seasonal affective disorder. (2011) (38)
Drug Therapy for Rheumatoid Arthritis in Adults: An Update (2012) (38)
Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and metaanalysis. (2008) (38)
Inadequate use and regulation of interventions against publication bias decreases their effectiveness: a systematic review (2015) (37)
Adjunct ultrasonography for breast cancer screening in women at average risk: a systematic review. (2013) (35)
Kyphoplastie und Vertebroplastie bei osteoporotischen Wirbelkörperkompressionsfrakturen (2009) (35)
Second-generation antidepressants for preventing seasonal affective disorder in adults. (2014) (34)
Findings of Bayesian Mixed Treatment Comparison Meta-Analyses: Comparison and Exploration Using Real-World Trial Data and Simulation (2013) (33)
Trading certainty for speed - how much uncertainty are decisionmakers and guideline developers willing to accept when using rapid reviews: an international survey (2017) (33)
Efficacy and tolerability of second-generation antidepressants in social anxiety disorder (2008) (33)
Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis. (2018) (32)
Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project (2009) (32)
The General and Comparative Efficacy and Safety of Duloxetine in Major Depressive Disorder (2009) (32)
Salt in health and disease--a delicate balance. (2013) (32)
Nonpharmacological Versus Pharmacological Treatments for Adult Patients With Major Depressive Disorder. (2015) (31)
Management of Eating Disorders Evidence Report (2006) (31)
Taxation of unprocessed sugar or sugar‐added foods for reducing their consumption and preventing obesity or other adverse health outcomes (2016) (30)
Interventions for the Prevention of Posttraumatic Stress Disorder (PTSD) in Adults After Exposure to Psychological Trauma (2013) (29)
CLINICAL HETEROGENEITY IN SYSTEMATIC REVIEWS AND HEALTH TECHNOLOGY ASSESSMENTS: SYNTHESIS OF GUIDANCE DOCUMENTS AND THE LITERATURE (2012) (28)
[Quarantine Alone or in Combination with Other Public Health Measures to Control COVID-19: A Rapid Review (Review)]. (2020) (28)
Psychological therapies for preventing seasonal affective disorder. (2015) (28)
Continuing education for the prevention of mild cognitive impairment and Alzheimer’s-type dementia: a systematic review and overview of systematic reviews (2019) (27)
[Kyphoplasty and vertebroplasty for the management of osteoporotic vertebral compression fractures: a systematic review]. (2009) (27)
Comparative Benefits and Harms of Complementary and Alternative Medicine Therapies for Initial Treatment of Major Depressive Disorder: Systematic Review and Meta-Analysis. (2017) (27)
Risikokommunikation in gesundheitsbedrohlichen Krisensituationen: Zusammenfassung einer WHO-Leitlinie (2019) (26)
Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. (2013) (26)
Taxation of sugar‐sweetened beverages for reducing their consumption and preventing obesity or other adverse health outcomes (2016) (26)
Comparative Effectiveness of Drug Therapy for Rheumatoid Arthritis and Psoriatic Arthritis in Adults (2007) (25)
Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis (2021) (23)
The effect of study sponsorship on a systematically evaluated body of evidence of head-to-head trials was modest: secondary analysis of a systematic review. (2010) (23)
Is the Cochrane collaboration prepared for the era of patient-centred outcomes research? (2013) (23)
Differences in Efficacy and Safety of Pharmaceutical Treatments between Men and Women: An Umbrella Review (2010) (23)
How Should Primary Care Doctors Select Which Antidepressants to Administer? (2012) (23)
Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review (2020) (22)
Mixed Treatment Comparison of the Treatment Discontinuations of Biologic Disease-Modifying Antirheumatic Drugs in Adults with Rheumatoid Arthritis (2012) (21)
Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review (2016) (20)
Comparative Efficacy and Risk of Harms of Immediate- versus Extended-Release Second-Generation Antidepressants: A Systematic Review with Network Meta-Analysis (2014) (20)
Drug Class Review: Second-Generation Antidepressants (2011) (20)
[Table], National Institute for Health and Clinical Excellence (NICE) (2010) (19)
Methodenhandbuch für Health-Technology-Assessment, Version 1.2012 (2012) (19)
Barriers to and facilitators of interventions to counter publication bias: thematic analysis of scholarly articles and stakeholder interviews (2014) (19)
Assessment of adverse effects and applicability--two areas not (yet) covered adequately in Cochrane reports. (2008) (19)
Developing trustworthy recommendations as part of an urgent response (1–2 weeks): a GRADE concept paper (2020) (19)
Assessing the accuracy of machine-assisted abstract screening with DistillerAI: a user study (2019) (19)
[GRADE guidelines: 4. Rating the quality of evidence - limitations of clinical trials (risk of bias)]. (2012) (18)
Ezetimibe-Statin Combination Therapy. (2016) (18)
Screening for Hypertension in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. (2020) (17)
Continuing education for the prevention of mild cognitive impairment and Alzheimer’s-type dementia: a systematic review protocol (2017) (17)
Effectiveness evaluation of a health promotion programme in primary schools: a cluster randomised controlled trial (2016) (17)
GRADE Leitlinien: 6. Einschätzung der Qualität der Evidenz – Unzureichende Präzision ☆ (2012) (16)
The methodological quality is insufficient in clinical practice guidelines in the context of COVID-19: systematic review (2021) (16)
The predictive validity of quality of evidence grades for the stability of effect estimates was low: a meta-epidemiological study. (2016) (16)
Quantitative Synthesis—An Update (2018) (16)
[GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence]. (2020) (16)
[GRADE equity guidelines 1: considering health equity in GRADE guideline development: introduction and rationale]. (2019) (15)
Melatonin and agomelatine for preventing seasonal affective disorder: a Cochrane Review (2015) (15)
Melatonin and agomelatine for preventing seasonal affective disorder. (2019) (15)
Community-based participatory research: A summary of the evidence (2004) (15)
Systematische Übersichtsarbeiten und Meta-Analysen (2007) (14)
Point-of-Care Ultrasonography in Patients With Acute Dyspnea: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians (2021) (14)
Comparison of transcatheter aortic valve implantation with other approaches to treat aortic valve stenosis: a systematic review and meta-analysis (2019) (13)
German language questionnaires for assessing implementation constructs and outcomes of psychosocial and health-related interventions: a systematic review (2018) (13)
Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update (2018) (13)
GRADE: Von der Evidenz zur Empfehlung oder Entscheidung - ein systematischer und transparenter Ansatz, um gut informierte Entscheidungen im Gesundheitswesen zu treffen. 1: Einleitung (2018) (13)
Resource use during systematic review production varies widely: a scoping review. (2021) (13)
Inadequate reporting of trials compromises the applicability of systematic reviews (2009) (12)
Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis (2019) (12)
Taxation of the fat content of foods for reducing their consumption and preventing obesity or other adverse health outcomes (2016) (12)
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer). (2018) (12)
Citation screening using crowdsourcing and machine learning produced accurate results: evaluation of Cochrane's modified Screen4Me service. (2020) (12)
GRADE Leitlinien: 5. Einschätzung der Qualität der Evidenz – Publikationsbias (2012) (11)
[GRADE guidelines: 6. Rating the quality of evidence: imprecision]. (2012) (11)
Immediate versus delayed surgery for hip fractures in the elderly patients: a protocol for a systematic review and meta-analysis (2017) (11)
Assessing the validity of abbreviated literature searches for rapid reviews: protocol of a non-inferiority and meta-epidemiologic study (2016) (11)
Household interventions for secondary prevention of domestic lead exposure in children. (2020) (11)
[GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations]. (2014) (10)
[GRADE guidelines: 12. Developing Summary of Findings tables - dichotomous outcomes]. (2013) (10)
GRADE Leitlinien: 14. Von der Evidenz zur Empfehlung: Die Bedeutung und Darstellung von Empfehlungen (2014) (10)
Abbreviated and comprehensive literature searches led to identical or very similar effect estimates: meta-epidemiological study. (2020) (10)
Drug Class Review: Second-Generation Antidepressants: Final Update 5 Report (2011) (10)
Drug Class Review: Constipation Drugs (2007) (10)
GRADE-Leitlinien: 2. Formulierung der Fragestellung und Entscheidung über wichtige Endpunkte (2012) (10)
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review. (2017) (9)
Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression [Internet] (2007) (9)
Participants’ expectations and experiences with periodic health examinations in Austria - a qualitative study (2018) (9)
Combining abbreviated literature searches with single-reviewer screening: three case studies of rapid reviews (2020) (9)
Drug Class Review: Targeted Immune Modulators (2012) (9)
Julius Wagner-Jauregg: pyrotherapy, simultanmethode, and ‘racial hygiene’ (2012) (9)
The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days (2020) (9)
Implementing prevention of seasonal affective disorder from patients’ and physicians’ perspectives – a qualitative study (2018) (9)
A case study of pooled-studies publications indicated potential for both valuable information and bias. (2013) (8)
Comparison of Precision (2013) (8)
GRADE Leitlinien: 7. Einschätzung der Qualität der Evidenz – Inkonsistenz (2012) (8)
Community gardening, community farming and other local community-based gardening interventions to prevent overweight and obesity in high-income and middle-income countries: protocol for a systematic review (2017) (8)
Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report (2012) (8)
Drug Class Review on Second Generation Antidepressants: Final Report (2006) (8)
Strategies in assessing the need for updating evidence-based guidelines for six clinical topics: an exploration of two search methodologies. (2008) (8)
Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. (2022) (8)
User testing of an adaptation of fishbone diagrams to depict results of systematic reviews (2017) (8)
Randomisiert kontrollierte Studien (2008) (8)
Video Teleconferencing for Disease Prevention, Diagnosis, and Treatment (2021) (7)
Grades for quality of evidence were associated with distinct likelihoods that treatment effects will remain stable. (2015) (7)
Drug Class Review: Alzheimer's Drugs: Final Report (2006) (7)
[How evidence-based are print- and online mass media in Austria? A quantitative analysis]. (2015) (7)
GRADE-Leitlinien: 12. Erstellen von „Summary-of-Findings“-Tabellen – Dichotome Endpunkte (2013) (7)
The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review (2019) (7)
Österreichische Patienteninformationsmaterialien zu PSA-Screening entsprechen nicht internationalen evidenzbasierten Standards (2011) (7)
GRADE-Leitlinien: 16. Von der Evidenz zur Empfehlung oder Entscheidung – Vorgehen nach GRADE für Tests in der klinischen Praxis und in Public Health (2018) (7)
Effectiveness of interventions for the remediation of lead-contaminated soil to prevent or reduce lead exposure - A systematic review (2022) (6)
Drug Class Review on Inhaled Corticosteroids (2006) (6)
Evidence-based medicine breaking the borders – A working model for the European Union to facilitate evidence-based health care (2004) (6)
How contextual issues can distort shared decision making. (2016) (6)
Cochrane Depression, Anxiety and Neurosis Group (CCDAN) Topic List: Intervention – Psychological Therapies (2015) (6)
Light therapy for preventing seasonal affective disorder. (2019) (6)
Comparative Benefits and Harms of Antidepressant, Psychological, Complementary, and Exercise Treatments for Major Depression (2016) (6)
Bewertung des Risikos für Bias in kontrollierten Studien (2014) (6)
WHO-Leitlinie: Prävention und Kontrolle von Tuberkulose-Infektionen (2020) (5)
Are some antidepressants better than others? (2009) (5)
Drug Class Review: Targeted Immune Modulators: Final Report Update 2 (2009) (5)
A case report of a 40-year-old woman with endomyocardial fibrosis in a non-tropical area: from initial presentation to high urgent heart transplantation (2019) (5)
Drug Class Review: Second Generation Antidepressants: Final Report Update 4 (2008) (5)
[GRADE equity guidelines 2: considering health equity in GRADE guideline development: equity extension of the guideline development checklist]. (2019) (5)
Appendix A. Search Strategy (2006) (5)
Rheopherese® bei altersbedingter Makuladegeneration (2009) (5)
Table 7, Summary of common statistical approaches to test for heterogeneity (2010) (5)
[Randomised controlled trials]. (2008) (5)
Pharmaceutical company-sponsored drug trials: the system is broken. (2010) (5)
Paracoccidioidomycosis Diagnosed in Europe—A Systematic Literature Review (2021) (5)
Screening for periodontal diseases by non-dental health professionals: a protocol for a systematic review and overview of reviews (2019) (5)
Quarantäne alleine oder in Kombination mit weiteren Public-Health-Maßnahmen zur Eindämmung der COVID-19 Pandemie: Ein Cochrane Rapid Review (2020) (5)
GRADE Leitlinien: 8. Einschätzung der Qualität der Evidenz – Indirektheit☆ (2012) (5)
Community-based participatory research: A summary of the evidence. Volume I. Evidence report (2004) (5)
SAMURAI: Sensitivity analysis of a meta-analysis with unpublished but registered analytical investigations (software) (2014) (5)
GRADE-Leitlinien: 9. Heraufstufen der Qualität der Evidenz (2013) (5)
Drug class review on targeted immune modulators: final report (2007) (5)
The impact of inclusion criteria in health economic assessments (2011) (4)
Nivolumab for adult individuals with Hodgkin lymphoma (an exemplar rapid review using RobotReviewer) (2017) (4)
Reaching out to Europe—Cochrane Public Health Europe and its research agenda. (2016) (4)
Comparative effectiveness reviews and the impact of funding bias. (2010) (4)
Psychological therapies for preventing seasonal affective disorder. (2019) (4)
Are all antidepressants equal? (2009) (4)
Comparative Benefits and Harms of Second-generation Antidepressants in the Pharmacologic Treatment of Depression in Older Adults: Systematic Revview and Network Meta-analysis (2015) (4)
Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: An Evidence Review for the U.S. Preventive Services Task Force (2017) (4)
Comparative bene fi ts and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder : systematic review and meta-analysis (2016) (4)
Rapid reviews methods series: Guidance on literature search (2023) (3)
[Comparative evaluation of information products regarding cancer screening of German-speaking cancer organizations]. (2014) (3)
Rapid reviews methods series: Guidance on team considerations, study selection, data extraction and risk of bias assessment (2023) (3)
GRADE-Leitlinien: 11. Gesamtbeurteilung des Vertrauens in Effektschätzer für einen einzelnen Studienendpunkt und für alle Endpunkte (2013) (3)
[Assessment of risk of bias in controlled studies]. (2014) (3)
[Austrian patient information materials on PSA-screening do not meet international evidence-based standards]. (2011) (3)
Drug Class Review: Inhaled Corticosteroids: Final Report (2006) (3)
Prevalence of Mental Disorders in Young Refugees and Asylum-Seekers in European Countries (2018) (3)
[WHO Guideline: Physical Activity, Sedentary Behavior and Sleep for Children under 5 Years of Age]. (2021) (3)
Assessing the magnitude of reporting bias in trials of homeopathy: a cross-sectional study and meta-analysis (2022) (3)
Health information for patients and the general public (2010) (3)
Second-generation antidepressants for treatment of seasonal affective disorder. (2021) (3)
Second-generation antidepressants for preventing seasonal affective disorder in adults. (2019) (3)
Drug Class Review: Targeted Immune Modulators: Final Update 3 Report (2012) (3)
[LDL apheresis for the treatment of familial hypercholesterolemia. A systematic review]. (2009) (3)
[Comparative effectiveness and safety of screening and counselling interventions conducted by non-physicians and physicians: a systematic review]. (2015) (3)
Diagnostische Studien (2008) (3)
Average effect estimates remain similar as evidence evolves from single trials to high-quality bodies of evidence: a meta-epidemiologic study. (2016) (3)
Perioperatives Anämiemanagement – Systematischer Review und Meta-Analyse (2014) (3)
Outpatient Treatment of Confirmed COVID-19 (2022) (3)
Ranking antidepressants (2009) (3)
Comparative efficacy, effectiveness and harms of second-generation antidepressants in the pharmacologic treatment of adult depression (2011) (2)
P-504 - the Comparative Effectiveness of Second-generation Antidepressants for the Accompanying Symptoms of Depression: a Systematic Review (2012) (2)
[Guideline development: Going from evidence to recommendations. Challenges and opportunities--a methodologist's view]. (2015) (2)
Mixed Treatment Comparisons Results: ACR 20 and ACR 70 (2012) (2)
The Effectiveness of Quarantine to Control the Coronavirus Disease 2019: A Rapid Review (2020) (2)
Authors' reply to comment on: a simple and valid tool distinguished efficacy from effectiveness studies (2007) (2)
A web-survey assessed attitudes toward evidence-based practice among psychotherapists in Austria (2022) (2)
[Evidence-based recommendations for the revision of the Austrian periodic health examination]. (2019) (2)
GRADE Leitlinien: 13. Erstellen von Summary-of-Findings-Tabellen und Evidenzprofilen – kontinuierliche Endpunkte (2014) (2)
WHO-Leitlinie: Beratung von Müttern zur Verbesserung von Stillpraktiken (2019) (2)
Summary of Findings Tables (2015) (2)
Cost‐conscious high‐quality care and guideline development education: a strange contradiction or simple solution? (2019) (2)
Surgical and Non-Surgical Interventions in Complete Rotator Cuff Tears. (2020) (2)
Drug Class Review: Constipation Drugs: Final Report [Internet] (2007) (2)
GRADE-Leitlinien: 10. Den Ressourcenverbrauch berücksichtigen und die Qualität ökonomischer Evidenz bewerten (2013) (2)
GRADE-Leitlinien zu Gerechtigkeit 2. Berücksichtigung der Gerechtigkeit im Gesundheitswesen bei der Entwicklung von GRADE-Leitlinien: Erweiterung der Checkliste zur Entwicklung von Leitlinien (2019) (2)
Results of Analyses (2013) (2)
Comparative Beneﬁts and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder An Updated Meta-analysis (2011) (2)
GRADE-Leitlinien zu Gerechtigkeit 1. Berücksichtigung der Gerechtigkeit im Gesundheitswesen bei der Entwicklung von GRADE-Leitlinien: Einführung und Hintergründe (2019) (2)
Efficacy and Harms of Second-generation Antidepressants for the Prevention of Seasonal Affective Disorder: a Systematic Review (2015) (1)
Forest plot of meta-analysis (2012) (1)
Authors’ Reply to Pereira Ribeiro et al.: Comment on “Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta‑Analysis” (2021) (1)
Characteristics of excluded studies for poor quality (2011) (1)
[Health Technology Assessment--evaluating health care interventions]. (2008) (1)
What are the Relevant Outcomes of the Periodic Health Examination? A Comparison of Citizens’ and Experts’ Ratings (2021) (1)
Second‐generation antidepressants for seasonal affective disorder (SAD) (2010) (1)
Data Abstraction Forms (2011) (1)
Reply to letter to the editor “Lessons from COVID-19 to future evidence synthesis efforts: first living search strategy and out of date scientific publishing and indexing industry” (2020) (1)
Assessing the Accuracy of Machine-Assisted Abstract Screening With DistillerAI: A User Study. Methods Research Report (2019) (1)
Screening for Hypertension in Children and Adolescents: Updated Evidence Report and Systematic Review for the USPSTF (2020) (1)
Drug Class Review: Second-Generation Antidepressants: Final Update 5 Report [Internet]. (2011) (1)
Cost-Effectiveness of First- and Second-Step Treatment Strategies for Major Depressive Disorder (2023) (1)
Preventing and treating PTSD and related conditions in adults: A research agenda (2013) (1)
Abbreviations and Full Names of Diagnostic Scales and Other Instruments (2011) (1)
[Table], Agency for Healthcare Research and Quality (AHRQ) final reports (2010) (1)
The Effectiveness of Quarantine alone or in Combination with Other Public Health Measures to Control Coronavirus Disease 2019: a Rapid Review (2020) (1)
P-505 - Comparative Benefits and Harms of Second-generation Antidepressants in the Pharmacologic Treatment of Depression in Older Adults and Populations With Comorbid Conditions (2012) (1)
The comparative efficacy of second-generation antidepressants for the accompanying symptoms of depression: a systematic review (2011) (1)
Immediate-release and extended-release formulations of second-generation antidepressants for the treatment of major depressive disorder in adults (2011) (1)
Drug Class Review: Targeted Immune Modulators: Final Report Update 2 [Internet] (2009) (1)
The Incidence of SARS-COV-2 Manifestations in the Central Nervous System: A Rapid Review and Meta-Analysis (2020) (1)
Effects of exposure to night shift work on cancer risk in workers (2019) (1)
Crowdsourcing the identification of studies for COVID‐19‐related Cochrane Rapid Reviews (2022) (1)
[Second-generation antidepressants] (2007) (1)
[Serie: Das Grading of Recommendations, Assessment, Development and Evaluation (GRADE) System]. (2019) (1)
GRADE Working Group (2019). GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. Clinical Epidemiology 105-114. (2018) (1)
No difference among new antidepressants (2005) (1)
Aromatherapy for pain relief and psychological problems. Systematic review (2008) (1)
Rapid reviews methods series: Guidance on assessing the certainty of evidence (2023) (1)
Wissensbasierte Maßnahmen zur Steigerung der Impfraten gegen Masern (2019) (1)
Minimal-invasiver perkutaner Aortenklappenersatz: eine systematische Übersichtsarbeit (2009) (1)
Health Technology Assessment – die Bewertung medizinischer Interventionen (2008) (1)
Nutzen-Schaden Abwägung von bevölkerungsbezogenen Interventionen am Beispiel von Krebs-Screening (2011) (1)
Diagnostische Studien. [Diagnostic studies.] (2009) (1)
[GRADE equity guidelines 3: considering health equity in GRADE guideline development: rating the certainty of synthesized evidence]. (2020) (1)
Values and Preferences of Patients With Depressive Disorders Regarding Pharmacologic and Nonpharmacologic Treatments (2023) (1)
Evidenzbasierte Medizin in der Praxis (2012) (1)
Leitlinienentwicklung: von der Evidenz zu Empfehlungen Möglichkeiten und Herausforderungen aus Sicht der MethodikerInnen (2015) (1)
GRADE Evidence-to-Decision-Tabellen für die Übernahme, Anpassung und De-novo-Entwicklung von vertrauenswürdigen Empfehlungen: GRADE-ADOLOPMENT (2019) (1)
Low-Density-Lipoprotein-Apherese bei familiärer Hypercholesterinämie (2009) (1)
GRADE-Leitlinien: 18. Wie ROBINS-I und andere Instrumente zur Einschätzung des Risikos für Bias von nicht-randomisierten Studien verwendet werden sollten, um die Vertrauenswürdigkeit eines Evidenzkörpers zu bewerten (2020) (1)
Quantifying the unquantifiable. (2012) (1)
Crowdsourcing and COVID-19: a case study of Cochrane Crowd (2021) (1)
Table 55, Malignancies in patients with rheumatoid arthritis and treated with biologic DMARDs (2012) (0)
[Table], Drug Effectiveness Review Program (DERP) reports (2010) (0)
Impact of the STAR*D trial from the perspective of the payer. (2009) (0)
Results: Narrative Review Key Questions (2018) (0)
Table 21, Radiographic joint damage biologic DMARD+oral DMARD versus biologic DMARD studies (2012) (0)
Figure 20, SGA versus cognitive behavioral therapy: Discontinuation rates because of lack of efficacy (2015) (0)
Figure 15, Comparison of discontinuation because of adverse events rates of SGA with other eligible interventions (relative risks and 95% confidence intervals) (2015) (0)
Table E-12, Comparison of ACR50 response for biologic DMARDs for placebo star sub-network, by method of analysis: Odds ratios (95% credible interval or 95% confidence interval) (2013) (0)
Figure 11, SGA versus St. John’s wort: Remission (2015) (0)
Appendix B. Abstract-only Studies (2007) (0)
Percutaneous aortic valve replacement. Systematic review (2008) (0)
Figure 4, Simulation study design (2013) (0)
[Table, August 2010 Search]. (2012) (0)
Table 4, Comparison of findings for mean change in HAM-D between Bayesian MTC meta-analysis findings and those of frequentist methods: agreement and kappas (2013) (0)
Clinical practice guidelines and recommendations in the context of the COVID-19 pandemic: systematic review and critical appraisal (2020) (0)
Table 12, Radiographic joint damage in oral DMARD combinations versus monotherapy combinations with or without corticosteroid studies (2012) (0)
Table 51, Cardiovascular and cerebrovascular events in patients with rheumatoid arthritis and treated with biologic DMARDs (2012) (0)
Table 57, Studies assessing adherence in patients with rheumatoid arthritis (2012) (0)
Studies with poor internal validity (2012) (0)
Table 44, Infection in patients with rheumatoid arthritis treated with oral DMARDs (2012) (0)
[Table], Health Technology Assessment (HTA) final reports (2010) (0)
Table B-1, Summary of studies included in analyses of response for second-generation antidepressants (2013) (0)
Table 9, Measures of model fit for second-generation antidepressants for response (2013) (0)
Table 2, Overview of studies identified by the EPC directors (2006) (0)
Chirurgische und nichtchirurgische Interventionen bei kompletten Rotatorenmanschettenrupturen: Ein systematisches Review mit Metaanalyse (2020) (0)
Figure 4, Network of trials included for network meta-analyses (2015) (0)
Children and adolescents with major depressive disorders: are some second generation antidepressants better than others? (2011) (0)
Table B-3, Summary of studies included in analyses of ACR50 response for biologic DMARDs (2013) (0)
Table 18, Simulation results: Probability of best treatment under superior efficacy scenario (2013) (0)
Table 52, Infections in patients with rheumatoid arthritis and treated with biologic DMARDs (2012) (0)
Table 50, Comparative harms in patients with rheumatoid arthritis and treated with biologic DMARDs (2012) (0)
Table 10, Probability of best treatment for second-generation antidepressants for response (2013) (0)
Table 14, Second-generation antidepressants versus third-wave cognitive behavioral therapy: Trial characteristics, main outcomes, and risk of bias ratings of trials (2015) (0)
Impact of timing of surgery in elderly hip fracture patients: a systematic review and meta-analysis (2018) (0)
Studies Excluded at the Full-Text Level (2013) (0)
Table C3, Summary of methodologic publications regarding clinical heterogeneity (2010) (0)
Authors’ reply to Gøtzsche and Hamilton (2016) (0)
[Evidence informed decisions in the land of compromise]. (2015) (0)
[Table], Database of Abstracts of Reviews of Effects (DARE) final reports (2010) (0)
Table A-3, Example summary table for body of evidence (2010) (0)
Table G24, Strength of evidence for subgroup effects of history of child abuse (2013) (0)
Table 25, Second-generation antidepressant switch versus another second-step switch strategy: Trial characteristics, main outcomes, and risk of bias ratings (2015) (0)
Table 2, Elements to be included in a summary table characterizing the applicability of a body of studies (2010) (0)
Figure 26, SGA versus any psychological treatment: Rates of suicidal ideas or behaviors (2015) (0)
Table 3, Additional domains and their definitions (2013) (0)
Table 9, AHRQ’s use of clinical heterogeneity in key questions (2010) (0)
Table 1, Characteristics of individual studies that may affect applicability (2010) (0)
Table 1, Example of a qualitative summary of studies with no events in both groups (2010) (0)
Figure 2, Clinical heterogeneity is present but the relevance of the impact has to be determined on clinical grounds (2010) (0)
[Table], Cochrane final reports (2010) (0)
Table 8, Comparison of findings for ACR 50 response between Bayesian MTC meta-analysis findings and those of frequentist methods for various network patterns (2013) (0)
Table 61, Study characteristics, outcomes, and quality ratings of adult subpopulations with rheumatoid arthritis by comorbidities (2012) (0)
Figure 17, SGA versus psychological interventions as a class: Discontinuation rates because of lack of efficacy (2015) (0)
COVID-19 pandemic: Are hard lockdowns ineffective?: Why the Bendavid et al. Study does not provide sufficient evidence for this Assumption (2021) (0)
Abstract and Full-Text Form Fields (2013) (0)
Excluded Studies: Characteristics of Studies With Poor Internal Validity (2012) (0)
Producers and users of systematic reviews associate grades of quality of evidence with similar likelihoods that effects will remain stable (2014) (0)
Figure 5, Meta-analysis of withdrawals due to lack of efficacy in randomized controlled trials of biologic DMARDs (2012) (0)
Comparison of Effects as Evidence Evolves From Single Trials to High-Quality Bodies of Evidence (2015) (0)
pyrotherapy, simultanmethode, and 'racial hygiene' (2012) (0)
Optical coherence tomography. Systematic review (2008) (0)
Figure 22, SGA versus St. John’s wort: Overall risk for adverse events (2015) (0)
Table 33, Biologic DMARD plus oral DMARD versus biologic DMARD studies: functional capacity and health-related quality-of-life outcomes (2012) (0)
Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. (2023) (0)
Summary of Studies Included in Analyses (2013) (0)
Key Informant Questionnaire (2010) (0)
Figure 5, Results of Bayesian MTC meta-analysis for five scenarios: odds ratio (95% credible interval) comparing fluoxetine, paroxetine, and sertraline for achieving response (2013) (0)
Articles by Database Searched (2012) (0)
Table E-14, Comparison of ACR50 response for biologic DMARDs for one closed loop sub-network using Adalimumab, by method of analysis: Odds ratios (95% credible interval or 95% confidence interval) (2013) (0)
PMH5 THE COMPARATIVE EFFICACY OF SECOND-GENERATION ANTIDEPRESSANTS FORTHE ACUTE-PHASE TREATMENT OF MAJOR DEPRESSIVE DISORDER: A SYSTEMATIC REVIEW AND META-ANALYSIS (2007) (0)
Figure 7, SGA versus cognitive behavioral therapy: Remission (2015) (0)
Table 3, Abbreviations and full names of assessment scales and other instruments (2006) (0)
35 An ultra-rapid review approach: an innovative solution to make evidence more relevant for time-sensitive policy-making and providing guidance for health systems? (2019) (0)
Assessing the Accuracy of Machine-Assisted Abstract Screening With Distiller AI: Methods Report (2019) (0)
[Systematic reviews and meta-analysis]. (2008) (0)
Table 31, Studies of efficacy, effectiveness, and harms for patient subgroups (2007) (0)
Table A-2, Example summary table characterizing the applicability of a body of studies (2010) (0)
Table E-8, Comparison of mean change in HAM-D for second-generation antidepressants for placebo star sub-network, by method of analysis: Weighted mean difference (95% credible interval or 95% confidence interval) (2013) (0)
Figure 10, SGA versus St. John’s wort: Response (2015) (0)
Table 7, Number of head-to-head trials by drug comparison for rheumatoid arthritis (2012) (0)
Appendix D. Excluded Studies (2007) (0)
Table 22, Disease activity and remission for biologic DMARD+oral DMARD versus oral DMARD (2012) (0)
Drug class review of Alzheimer's drugs. Evdence report (2006) (0)
Table 42, Cardiovascular and cerebrovascular events in patients with rheumatoid arthritis treated with oral DMARDs (2012) (0)
Figure 9, SGA versus cognitive behavioral therapy: Change in HAM-D-17 (2015) (0)
Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-analysis for a Clinical Guideline by the American College of Physicians (2023) (0)
Appendix B. Clinical Assessment Scales Commonly Used in AD Therapeutic Trials (2006) (0)
Table 30, Biologic DMARD versus biologic DMARD studies: Functional capacity and health-related quality-of-life outcomes (2012) (0)
Figure 13, Comparison of overall risk of harms of SGAs with other eligible interventions (relative risks and 95% confidence intervals) (2015) (0)
Table 7, Comparison of findings for mean change in HAM-D between Bayesian MTC meta-analysis findings and those of frequentist methods for various network patterns (2013) (0)
Appendix F. Acknowledgements (2006) (0)
Review and Abstraction Forms (2012) (0)
Table 19, Topics for specific charge to the work group (2010) (0)
P-536 - Immediate-release and Extended-release Formulations of Second-generation Antidepressants for the Treatment of Major Depressive Disorder in Adults (2012) (0)
Table 15, Expected (mean) ACR 50 treatment response of biologic DMARDs (2012) (0)
Table 10, Radiographic joint damage in oral DMARD versus oral DMARD (2012) (0)
Table 39, Infection in patients with rheumatoid arthritis treated with corticosteroids (2012) (0)
Table 1, Required domains: definitions and scores (2013) (0)
Table 20, Advantages and disadvantages of the Bayesian MTC approach (2013) (0)
’ s response to reviews Title : Comparison of transcatheter aortic valve implantation with other approaches to treat aortic valve stenosis : a systematic review and meta-analysis (2019) (0)
[Table], Abstract Review Questions (2012) (0)
Table 23, Radiographic joint damage of biologic DMARD+oral DMARD versus oral DMARD (2012) (0)
Table 18, Radiographic joint damage in biologic DMARDs versus oral DMARD studies (2012) (0)
WinBUGS Code Used in Bayesian Mixed Treatment Comparisons Meta-Analysis (2013) (0)
LDL apheresis. Systematic review (2008) (0)
Table 26, Second-generation antidepressant augmentation versus another second-generation augmentation strategy: Trial characteristics, main outcomes, and risk of bias ratings (2015) (0)
Table 17, Bias of simulation results: Difference between observed and expected probability of best treatment under equivalent efficacy scenario (2013) (0)
Studies Recommended for Inclusion by Peer and Public Reviewers (2011) (0)
Table 16, Second-generation antidepressants versus omega-3 fatty acids: Study characteristics, main outcomes, and risk of bias ratings (2015) (0)
Table 6, Definitions of clinical heterogeneity by five organizations (2010) (0)
Abstract-only studies (not included) (2011) (0)
Table 17, Types of comments received on draft comparative effectiveness reviews (2010) (0)
Table 21, Comparative efficacy for critical efficacy outcomes by baseline severity for psychological interventions and second-generation antidepressants (2015) (0)
PTSD Outcome Measures and Instruments (2013) (0)
Table 9, Reported sources of funding for included trials (2015) (0)
Table 58, Study characteristics, outcomes, and quality ratings of adult subpopulations with rheumatoid arthritis: By stage of disease (2012) (0)
[New vaccines: Horizon scanning] (2007) (0)
Figure 25, SGA versus St. John’s wort: Discontinuation rates because of lack of efficacy (2015) (0)
Internal manual. Part 2 (2nd Ed.) (2009) (0)
Table 5, Summary of key outcomes, findings, and strength of evidencea (2013) (0)
Table 28, Number of included trials for all subgroups by type of comparison (2015) (0)
Figure 9, Mixed treatment comparisons for withdrawals due to adverse events in randomized controlled trials of biologic DMARDs (2012) (0)
Table 16, Simulation results: Probability of best treatment under equivalent efficacy scenario (2013) (0)
EPA-1042 – Immediate vs. Extended Release Second-Generation Antidepressants in the Treatment of Major Depressive Disorder – A Systematic Review (2014) (0)
Figure 10, Evidence network for continuous covariate meta-regression to assess whether efficacy of biologic DMARDs differs for patients with longer disease duration (2013) (0)
Assessing the Predictive Validity of Quality of Evidence Grades in Systematic Reviews. A Meta-Epidemiological Study (2016) (0)
Mixed Treatment Comparisons Sensitivity Analysis Methods (2012) (0)
Prävention der Mutter-zu-Kind-Übertragung des Hepatitis-B-Virus: Leitlinie zur antiviralen Prophylaxe während der Schwangerschaft (2022) (0)
WHO-Leitlinie: Leitfaden für die medikamentöse Behandlung von Bluthochdruck bei Erwachsenen (2023) (0)
Systematische Ubersichtsarbeiten und meta-analysen. [Systematic reviews and meta-analysis] (2008) (0)
Evidenzbasierte Empfehlungen zur Überarbeitung der österreichischen Vorsorgeuntersuchung (2019) (0)
Kohortenstudien. [Cohort studies.] (2008) (0)
Klinische Ergebnisse, gesundheitsbezogene Lebensqualität und Kosten-Effektivität eines 6-monatigen Programms zur Lebensstilmodifikation bei Personen mit erhöhtem kardioväskularen Risiko in Niederösterreich (2012) (0)
Table 4, Number of unduplicated reports identified from the Cochrane Library, DARE, and HTA databases (2010) (0)
GRADE-Leitlinien zu Gerechtigkeit 4. Berücksichtigung der Gerechtigkeit im Gesundheitswesen bei der Entwicklung von GRADE-Leitlinien: von der Evidenz zur Empfehlung (2020) (0)
WHO-Leitlinie: Körperliche Aktivität, Bewegungsmangel und Schlaf für Kinder unter 5 Jahren (2021) (0)
GRADE-Leitlinien: 17. Beurteilung des Bias-Risikos durch fehlende Endpunkt-Daten im Evidenzkörper (2019) (0)
Klinische Ergebnisse, gesundheitsbezogene Lebensqualität und Kosten-Effektivität eines 6-monatigen Programms zur Lebensstilmodifikation bei Personen mit erhöhtem kardiovaskulären Risiko in Niederösterreich (2012) (0)
GRADE-Leitlinien zu Gerechtigkeit 3: Berücksichtigung der Gerechtigkeit im Gesundheitswesen bei der Entwicklung von GRADE-Leitlinien: Vertrauenswürdigkeit der Evidenz beurteilen (2020) (0)
Figure 3, Clinical heterogeneity is present and leads to a clinically relevant impact on the treatment effect (reversed direction) (2010) (0)
Table 4, Pharmaceutical treatments for rheumatoid arthritis: Biologic DMARDs (2012) (0)
Figure 9, Odds ratios (95% credible interval) of treatment response for second-generation antidepressants, by patient population (2013) (0)
Sozialkapital und Public Health (2020) (0)
Bewertung der Validität eines Ultra-Rapid Review Ansatzes: drei Fallstudien aus den Bereichen Onkologie und Public Health (2019) (0)
Empfehlungen der Österreichischen Gesellschaft für Public Health (ÖPGH) gegen Überversorgung – ein Projekt von Gemeinsam gut entscheiden – Choosing Wisely Austria (2020) (0)
Table 27, Number of trials for each comparison of interest (2015) (0)
Table B-2, Summary of studies included in analyses of mean change in HAM-D for second-generation antidepressants (2013) (0)
Filamentous Fungal Infections in a Tertiary Care Setting: Epidemiology and Clinical Outcome (2021) (0)
Characteristics and recovery methods of studies falsely excluded during literature screening—a systematic review (2021) (0)
Distribution Plots From Simulation Study (2013) (0)
Table 13, Second-generation antidepressants versus psychodynamic therapies: Trial characteristics, main outcomes, and risk of bias ratings (2015) (0)
Table 12, Measures of model fit for biologic DMARDs for rheumatoid arthritis for achieving ACR 50 (2013) (0)
Table 2, Definitions and descriptions of reporting bias (2013) (0)
Studies Included in Network Meta-Analyses (2015) (0)
Pharmacokinetic properties and drug interactions (2011) (0)
Table 8, Summary of relationships between clinical and statistical heterogeneity (2010) (0)
Table A, Summary of findings with strength of evidence (2012) (0)
Table 27, Radiographic joint damage in early RA strategy studies (2012) (0)
Table 2, Key questions for methods report on clinical heterogeneity (2010) (0)
Figure 12, SGA versus St. John’s wort: Change in HAM-D-17 (2015) (0)
[Figure], Relative Treatment Effect for ACR20 Response (2012) (0)
Table 22, SGAs versus SAMe by depression severity: Trial characteristics, main outcomes, and risk of bias ratings of trials (2015) (0)
Table 3, Pharmaceutical treatments for rheumatoid arthritis: Oral DMARDs (2012) (0)
Table 16, Evidence profile of comparisons of targeted immune modulators for the treatment of psoriatic arthritis in children (2009) (0)
Table C1, Guidance documents describing clinical heterogeneity issues (2010) (0)
Table 2, Pharmaceutical treatments for rheumatoid arthritis: Corticosteroids (2012) (0)
In Reply. (2017) (0)
Table 47, Other specific adverse events in patients with rheumatoid arthritis treated with oral DMARDs (2012) (0)
Table 48, Overall tolerability: randomized controlled trials included in withdrawal quantitative analyses (2012) (0)
Table 41, Overall tolerability in patients with rheumatoid arthritis treated with oral DMARDs (2012) (0)
Table 45, Interstitial lung disease in patients with rheumatoid arthritis treated with oral DMARDs (2012) (0)
Evidence Table 25, KQ 4. General Tolerability: Tier 2 (rTMS vs. sham—MDD only) (2011) (0)
Figure 27, SGA versus St. John’s wort: Serious adverse events (2015) (0)
Cochrane Review: Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents (2012) (0)
Randomized controlled trials (2007) (0)
Selective Cell Apheresis in Inflammatory Bowel Disease (2008) (0)
Table D-4, Comparison of response for second-generation antidepressants for placebo star sub-network, by method of analysis: Odds ratios (95% credible interval or 95% confidence interval) (2013) (0)
Author ’ s response to reviews Title : USER TESTING OF AN ADAPTATION OF FISHBONE DIAGRAMS TO DEPICT RESULTS OF SYSTEMATIC REVIEWS Authors : (2017) (0)
Table 1, ACR criteria for the diagnosis of rheumatoid arthritis (2012) (0)
Figure 4, Relation between clinical heterogeneity and applicability in systematic reviews (2010) (0)
Figure 7, Mixed treatment comparisons for overall withdrawals in randomized controlled trials of biologic DMARDs (2012) (0)
Risk of Bias Evaluations (2015) (0)
Figure 6, Meta-analysis of withdrawals due to adverse events in randomized controlled trials of biologic DMARDs (2012) (0)
Table 53, Infusion or injection site reactions in patients with rheumatoid arthritis and treated with biologic DMARDs (2012) (0)
Table 24, Disease activity and remission for biologic DMARD+oral DMARD versus biologic DMARD+oral DMARD (2012) (0)
Figure 14, Comparison of overall discontinuation rates from SGAs with other eligible interventions (relative risks and 95% confidence intervals) (2015) (0)
Bach Flower Remedies for pain relief and psychological problems. Systematic review (2008) (0)
Table A-1, Example evidence table of individual studies with key applicability factors abstracted and judgment of applicability (2010) (0)
Table 15, Second-generation antidepressants versus acupuncture: Study characteristics, main outcomes, and risk of bias ratings (2015) (0)
Drug Class Review Targeted Immune Modulators Draft Update 4 Report Final Approval (2014) (0)
Table 12, Second-generation antidepressants versus interpersonal psychotherapy: Trial characteristics, main outcomes, and risk of bias ratings (2015) (0)
Table 11, Disease activity and remission for oral DMARD combinations versus monotherapy or combinations with or without corticosteroid studies (2012) (0)
Figure A-1, Framework for examining risk of reporting bias (2013) (0)
Figure 8, SGA versus cognitive behavioral therapy: Response (2015) (0)
Table 18, Clustering of authors of publications about clinical heterogeneity (2010) (0)
Drug class review on second generation antidepressants: Final report [Internet] (2006) (0)
Using GRADE to develop the WHO guideline on verifying elimination of human onchocerciasis (2016) (0)
Randomisiert kontrollierte Studien. [Randomised controlled trails.] (2008) (0)
Table 1, Proposed criteria to distinguish effectiveness from efficacy trials (2006) (0)
Table 8, Abbreviations and full names of mental health and other assessment tools (2015) (0)
Table 60, Study characteristics, outcomes, and quality ratings of adult subpopulations with rheumatoid arthritis: By concomitant therapies (2012) (0)
Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction in patients with congenital heart defects. Systematic review (2008) (0)
Table B-2, [Intervention A] vs. [Intervention B] for the treatment of [Disease]: Details regarding strength of evidence domains (2013) (0)
Table 10, Cochrane Collaboration use of clinical heterogeneity in key questions (2010) (0)
Figure 11, Odds ratios (95% credible interval) of treatment response for Etanercept compared with other biologic DMARDs, with and without disease duration covariate (2013) (0)
Psychological impact of an epidemic/pandemic on the mental health of healthcare professionals: a rapid review (2020) (0)
Table 35, Biologic DMARD plus oral DMARD versus biologic DMARD plus oral DMARD studies: Functional capacity and health-related quality-of-life outcomes (2012) (0)
Clinical and Self-Reported Scales and Instruments Commonly Used in Studies of Drug Therapy for Rheumatoid Arthritis and Psoriatic Arthritis (2012) (0)
Appendix C. Quality Criteria (2006) (0)
Table 59, Study characteristics, outcomes, and quality ratings of adult subpopulations with rheumatoid arthritis: By age (2012) (0)
Table 23, Comparative efficacy for critical efficacy outcomes by baseline severity for complementary and alternative interventions, exercise, and second-generation antidepressants (2015) (0)
Figure 7, Results of Bayesian MTC meta-analysis for five scenarios: odds ratio (95% credible interval) comparing abatacept and infliximab for treatment response (ACR 50) (2013) (0)
Table 29, Oral DMARD combination studies: Functional capacity and health-related quality-of-life outcomes (2012) (0)
Graphical Options for Examining Contributions to Q (2018) (0)
Corticosteroids benefit patients with moderate to severe COPD. (2006) (0)
Assessing the Predictive Validity of Strength of Evidence Grades: A Meta-Epidemiological Study (2015) (0)
Sex-specific differences in prevention of type 2 diabetes mellitus: a systematic review and meta-analysis (2015) (0)
Table 13, Disease activity and remission for biologic DMARD versus biologic DMARD studies (2012) (0)
A web-survey assessed attitudes toward evidence-based practice among psychotherapists in Austria (2022) (0)
Table 14, Measures of model fit for main analysis and meta-regression (2013) (0)
Figure 1, Clinical heterogeneity is present but has a minimal impact on the treatment effect (2010) (0)
Poor-Quality Studies (2011) (0)
Table 56, Other specific adverse events in patients with rheumatoid arthritis and treated with biologic DMARDs (2012) (0)
Table 49, Overall tolerability: discontinuation data not otherwise covered by quantitative analyses (2012) (0)
Data From Network Meta-Analyses (2015) (0)
Table 40, Other specific harms in patients with rheumatoid arthritis treated with corticosteroids (2012) (0)
Table 46, Malignancies in patients with rheumatoid arthritis treated with oral DMARDs (2012) (0)
Table 54, Interstitial lung disease in patients with rheumatoid arthritis and treated with biologic DMARDs (2012) (0)
Table 5, Outcome measures and study eligibility criteria (2012) (0)
Figure 18, SGA versus psychological interventions as a class: Discontinuation rates because of adverse events (2015) (0)
Table 17, Disease activity and remission for biologic DMARD versus oral DMARD (2012) (0)
Appendix D. Characteristics of Excluded Studies (2006) (0)
Table 16, Clinical heterogeneity variables specified in key questions for AHRQ comparative effectiveness reviews (2010) (0)
Evidence-Based Medicine Breaking the Borders - The European Union as a Paradigm (2002) (0)
Appendix E. Abstract-only Studies (not included) (2006) (0)
Figure 3, PRISMA diagram for treatment of major depressive disorders (2015) (0)
Figure 8, Mixed treatment comparisons for withdrawals due to lack of efficacy in randomized controlled trials of biologic DMARDs (2012) (0)
Figure 3, Relative treatment effect for ACR 50 response for biologics (2012) (0)
Table 16, Exclusion criteria of MTC meta-analyses (2012) (0)
Figure 24, SGA versus St. John’s wort: Discontinuation because of adverse events (2015) (0)
Table 36, Early RA strategies: Functional capacity and health-related quality-of-life outcomes (2012) (0)
Methods for Drug Class Reviews for Oregon Health Plan Practitioner-Managed Prescription Drug Plan; Oregon Health and Science University Evidence-based Practice Center (2011) (0)
Component studies of included systematic reviews (2012) (0)
Figure 1, Phases of treatment for major depression (2015) (0)
Table 14, Summary of the 30 studies included in mixed treatment comparison meta-analysis (2012) (0)
Figure 12, One closed loop network pattern used in simulation (2013) (0)
Table 15, Use of demographic or disease variables in AHRQ systematic reviews (2010) (0)
Table 8, Disease activity, radiographic progression, functional capacity, and quality-of-life measures (2012) (0)
Studies Included in Mixed-Treatment Comparisons and Meta-analyses (2011) (0)
Table 11, Measures of model fit for second-generation antidepressants for mean change from baseline in HAM-D (2013) (0)
Table 2, Summary of key points and recommendations for quantitative synthesis in Comparative Effectiveness Reviews (2010) (0)
[Balancing benefits and harms of population-based interventions, using the example of cancer screening]. (2011) (0)
[Rheopheresis in patients with age-related macular degeneration, sudden hearing loss or tinnitus, diabetes. Systematic review] (2008) (0)
Table 1, Approach for Addressing Potential Sources of Heterogeneity (2012) (0)
Table 9, SSRIs versus SSRIs study characteristics, response and remission rates, and quality ratings of studies in adults with major depressive disorder (2011) (0)
Table 19, Second-generation antidepressants versus exercise: Study characteristics, main outcomes, and risk of bias ratings (2015) (0)
Figure 23, SGA versus St. John’s wort: Overall discontinuation rates (2015) (0)
Epidemiology, risk profile, management, and outcome in geriatric patients with atrial fibrillation in two long-term care hospitals (2022) (0)
Correction to: Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis (2020) (0)
Bibliography of References by Database Searched (2011) (0)
Figure 16, SGA versus psychological interventions as a class: Overall discontinuation rates (2015) (0)
Figure 8, Evidence network for subgroup meta-regression to assess whether efficacy of second-generation antidepressants differs for older adults (2013) (0)
Table 29, Second-generation antidepressants versus nonpharmacological therapies in subgroups: Trial characteristics, main outcomes, and risk of bias ratings (2015) (0)
Criteria for Assessing the Quality of Individual Studies (2012) (0)
Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Persons-Reply. (2023) (0)
Author Correction: A web-survey assessed attitudes toward evidence-based practice among psychotherapists in Austria (2022) (0)
Figure 21, SGA versus cognitive behavioral therapy: Discontinuation rates because of adverse events (2015) (0)
Black box warnings of drugs approved by the US Food and Drug Administration (2011) (0)
Table 11, Second-generation antidepressants versus cognitive behavioral therapy: Trial characteristics, main outcomes, and risk of bias ratings (2015) (0)
Barriers and facilitators in the implementation of interventions to prevent publication bias (2012) (0)
Figure 4, Meta-analysis of overall withdrawals from randomized controlled trials of biologic DMARDs (2012) (0)
Table 25, Radiographic joint damage for biologic DMARD+oral DMARD versus biologic DMARD+oral DMARD (2012) (0)
Table 21, Possible targets for future research, by Key Question (KQ) (2013) (0)
Figure 2, Evidence network for ACR 50 mixed treatment comparisons (2012) (0)
Example Gradeable Document (2015) (0)
Table 26, Disease activity and remission for early RA DMARD strategies (2012) (0)
Table 12, DERP use of clinical heterogeneity in key questions (2010) (0)
Instruments used to measure outcomes in trials involving targeted immune modulators (2012) (0)
Figure 19, SGA versus cognitive behavioral therapy: Overall discontinuation rates (2015) (0)
Table 15, Interaction effect and probability of best treatment (2013) (0)
Table 19, Disease activity and remission for biologic DMARD+biologic DMARD versus biologic DMARD studies (2012) (0)
Table 20, SGAs versus psychological interventions by depression severity: Trial characteristics, main outcomes, and risk of bias ratings of trials (2015) (0)
Figure 6, Comparison of remission rates of SGAs compared with other eligible interventions (relative risks and 95% confidence intervals) (2015) (0)
Table 3, Comparison of findings for SGA response between Bayesian MTC meta-analysis findings and those of frequentist methods: agreement and kappas (2013) (0)
Figure 1, Disposition of articles (PRISMA figure) (2012) (0)
Table 43, Hepatic events in patients with rheumatoid arthritis treated with oral DMARDs (2012) (0)
Author’s reply to Straton (2012) (0)
Table 38, Cardiovascular and cerebrovascular events in patients with rheumatoid arthritis treated with corticosteroids (2012) (0)
Searching two or more databases decreased the risk of missing relevant studies: a metaresearch study. (2022) (0)
Table 37, Overall tolerability in patients with rheumatoid arthritis treated with corticosteroids (2012) (0)
Table 18, Second-generation antidepressants versus St. John’s wort: Trial characteristics, main outcomes, and risk of bias ratings (2015) (0)
[Rheopheresis for age-related macular degeneration]. (2009) (0)
Table 6, Strength of evidence grades and their definitions (2012) (0)
Kyphoplasty and vertebroplasty for osteoporotic vertebral compression fractures. Systematic review (2008) (0)
Table B-1, [Intervention A] vs. [Intervention B] for the treatment of [Disease]: Strength of evidence domains (2013) (0)
Table 24, Number of included trials by type of comparison (2015) (0)
Figure 6, Results of Bayesian MTC meta-analysis for five scenarios: weighted mean difference (95% credible interval) comparing escitalopram, fluoxetine, and venlafaxine for mean change from baseline in HAM-D (2013) (0)
Figure 1, Major steps in a systematic review culminating in grading strength of evidence (2013) (0)
Table 13, Probability of best treatment for biologic DMARDs for rheumatoid arthritis for achieving ACR 50 (2013) (0)
Risk of Contrast-Associated Acute Kidney Injury in Patients Undergoing Peripheral Angiography with Carbon Dioxide Compared to Iodine-Containing Contrast Agents: A Systematic Review and Meta-Analysis (2022) (0)
Table 9, Disease activity and remission for oral DMARD versus oral DMARD studies (2012) (0)

This paper list is powered by the following services:

Other Resources About Gerald Gartlehner

en.wikipedia.org

What Schools Are Affiliated With Gerald Gartlehner?

Gerald Gartlehner is affiliated with the following schools:

Gerald Gartlehner's Academic­Influence.com Rankings

Gerald Gartlehner's Degrees

Why Is Gerald Gartlehner Influential?

Gerald Gartlehner's Published Works

Published Works

Other Resources About Gerald Gartlehner

What Schools Are Affiliated With Gerald Gartlehner?

Gerald Gartlehner's AcademicInfluence.com Rankings